HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Forssell-Aronsson, E. B. Articles by Ahlman, H. Search for Related Content PubMed PubMed Citation Articles by Forssell-Aronsson, E. B. Articles by Ahlman, H.

¹¹¹In-DTPA-D-Phe¹-Octreotide Binding and Somatostatin Receptor Subtypes in Thyroid Tumors

Departments of Radiation Physics, Pathology, and Surgery, Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden

Correspondence: For correspondence or reprints contact: Eva B. Forssell-Aronsson, PhD, Department of Radiation Physics, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden.

ABSTRACT

The purpose of this study was to evaluate the potential for therapy of thyroid tumors using the radiolabeled somatostatin (SS) analog octreotide. Methods: Concentrations of ¹¹¹ln activity in human thyroid tumors and normal thyroid tissue and blood samples were determined 1-15 d after intravenous injection of ¹In-diethylenetriaminepentaacetic acid-Phe¹-octreotide. The results were compared with SS receptor (sstr) subtype profile (by Northern blot analysis) and the relative expression of the second subtype, sstr2 (by ribonuclease protection assay, RPA). The true tumor volumes in lymph node metastases from 1 patient were estimated. In total, tissues from 68 patients were included in the study. Results: The highest tumor-to-blood ratio (T/B) for medullary thyroid carcinoma (MTC) was 360; for follicular adenoma (FA), 190; for Hürthle cell adenoma (HCA), 140; and for Hürthle cell carcinoma (HCC) and papillary carcinoma (PC), 70. The corresponding value was 7–18 for normal thyroid tissue, with higher values for colloid goiter (8–48) and thyroiditis (7–120). A high T/B was related to a large fraction of tumor cells in lymph node metastases. T/Bs were higher for the tumor samples with expression of sstr2 at Northern blot analysis than for those without. All thyroid tumor types regularly expressed sstr1, sstr3, sstr4, and sstr5. sstr2 was expressed in most MTC tumors but was not detected in FA or PC and was irregularly expressed in HCA and HCC. However, RPA analysis detected sstr2 in all tumors studied. Conclusion: Despite the lack of sstr2 at North-em blot analysis in most of the thyroid tumors studied, high T/Bs were in general found when compared with corresponding values for normal thyroid tissue. The sometimes extremely high ratios are promising and indicate a possibility of using radiolabeled octreotide for radiation therapy of ssfr-positive tumors in the future.

Key Words: octreotide • ¹¹¹In • thyroid tumors • somatostatin receptors

This article has been cited by other articles:

				M. Rodrigues, S. Li, M. Gabriel, D. Heute, M. Greifeneder, and I. Virgolini 99mTc-Depreotide Scintigraphy Versus 18F-FDG-PET in the Diagnosis of Radioiodine-Negative Thyroid Cancer J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3997 - 4000. [Abstract] [Full Text] [PDF]

				M. C. Zatelli, D. Piccin, F. Tagliati, A. Bottoni, A. Luchin, C. Vignali, A. Margutti, M. Bondanelli, G. C. Pansini, M. R. Pelizzo, et al. Selective Activation of Somatostatin Receptor Subtypes Differentially Modulates Secretion and Viability in Human Medullary Thyroid Carcinoma Primary Cultures: Potential Clinical Perspectives J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2218 - 2224. [Abstract] [Full Text] [PDF]

				M. Ginj, J. Chen, M. A. Walter, V. Eltschinger, J. C. Reubi, and H. R. Maecke Preclinical Evaluation of New and Highly Potent Analogues of Octreotide for Predictive Imaging and Targeted Radiotherapy Clin. Cancer Res., February 1, 2005; 11(3): 1136 - 1145. [Abstract] [Full Text] [PDF]

				J. J.M. Teunissen, D. J. Kwekkeboom, P. P.M. Kooij, W. H. Bakker, and E. P. Krenning Peptide Receptor Radionuclide Therapy for Non-Radioiodine-Avid Differentiated Thyroid Carcinoma J. Nucl. Med., January 1, 2005; 46(1_suppl): 107S - 114S. [Abstract] [Full Text] [PDF]

				M. Duet, E. Sauvaget, B. Petelle, N. Rizzo, J.-P. Guichard, M. Wassef, J. Le Cloirec, P. Herman, and P. Tran Ba Huy Clinical Impact of Somatostatin Receptor Scintigraphy in the Management of Paragangliomas of the Head and Neck J. Nucl. Med., November 1, 2003; 44(11): 1767 - 1774. [Abstract] [Full Text] [PDF]

				V. J. Lowe, B. P. Mullan, I. D. Hay, B. McIver, and J. L. Kasperbauer 18F-FDG PET of Patients with Hurthle Cell Carcinoma J. Nucl. Med., September 1, 2003; 44(9): 1402 - 1406. [Abstract] [Full Text] [PDF]

				J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]

				L. J. Hofland, S. W.J. Lamberts, P. M. van Hagen, J.-C. Reubi, J. Schaeffer, M. Waaijers, P. M. van Koetsveld, A. Srinivasan, E. P. Krenning, and W. A.P. Breeman Crucial Role for Somatostatin Receptor Subtype 2 in Determining the Uptake of [111In-DTPA-D-Phe1]Octreotide in Somatostatin Receptor-Positive Organs J. Nucl. Med., August 1, 2003; 44(8): 1315 - 1321. [Abstract] [Full Text] [PDF]

				M. Gabriel, C. Decristoforo, E. Donnemiller, H. Ulmer, C. Watfah Rychlinski, S. J. Mather, and R. Moncayo An Intrapatient Comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-Octreotide for Diagnosis of Somatostatin Receptor-Expressing Tumors J. Nucl. Med., May 1, 2003; 44(5): 708 - 716. [Abstract] [Full Text] [PDF]